



Expanded View Figures


A PFC extracts from CB1^{-/-} mice

B PFC extracts from CPPQ-treated WT mice


Figure EV1. Chronic intake of THC during adolescence does not induce mTOR activation in PFC of CB1^{-/-} mice and wild-type mice treated with CPPQ during adolescence.

A CB1^{-/-} mice were injected daily with THC (5 mg/kg) or vehicle (Veh) during adolescence, from PND 30 to 45. Top: representative Western blots assessing mTOR phosphorylation at S2448 and p70S6K phosphorylation at T389 as indexes of mTOR activity in the PFC of adult CB1^{-/-} mice are illustrated. Bottom: data represent the ratios of immunoreactive signals of the anti-phospho-mTOR (S2448) or anti-phospho-P70S6K (T389) antibodies to the immunoreactive signal of the anti-β-actin antibody and are expressed in % of values in vehicle-injected mice. They are the means ± SEM of results obtained in three mice per group. $P > 0.05$, unpaired Student's *t* test. n.s.: not significant.

B Wild-type mice were injected daily with THC (5 mg/kg) or vehicle (Veh) during adolescence, from PND 30 to 45. CPPQ (2.5 mg/kg) was administered concomitantly with vehicle or THC. Top: representative Western blots assessing mTOR phosphorylation at S2448 and p70S6K phosphorylation at T389 as indexes of mTOR activity in the PFC of adult WT mice are illustrated. Bottom: data represent the ratios of immunoreactive signals of the anti-phospho-mTOR (S2448) or anti-phospho-P70S6K (T389) antibodies to the immunoreactive signal of the anti-β-actin antibody and are expressed in % of values in vehicle-injected mice. They are the means ± SEM of results obtained in three mice per group. $P > 0.05$, unpaired Student's *t* test.

A Cyclotron**B**

Elevated plus maze

**Figure EV2. Chronic THC intake during adolescence does not induce an alteration in locomotion nor anxiety-related behavior.**

- A** Distance moved in the open field and percentage of time moving in the center of the open field. Distance moved: 706 ± 29 cm and 616 ± 51 cm for vehicle ($N = 8$) and THC ($N = 8$) conditions, respectively, $P > 0.05$, unpaired Student's *t* test. Time spent in the center: $19.18 \pm 1.69\%$ and $20.39 \pm 1.22\%$ for vehicle ($N = 8$) and THC ($N = 8$) conditions, respectively, $P > 0.05$, unpaired Student's *t* test. Errors bars correspond to the mean \pm SEM.
- B** Percentage of open arm time and entries in the EPM. Time spent in the open arm: $23.24 \pm 3.25\%$ and $18.86 \pm 3.45\%$ for vehicle ($N = 8$) and THC ($N = 8$), respectively, $P > 0.05$, unpaired Student's *t* test. Number of entries in the open arm: 15 ± 1 entries and 11 ± 2 entries for vehicle ($N = 8$) and THC ($N = 8$) conditions, respectively, $P > 0.05$, unpaired Student's *t* test. Errors bars correspond to the mean \pm SEM.






Figure EV3. Chronic THC administration to adult mice does not induce sustained mTOR activation and cognitive deficits.

A Schema of the experimental paradigm used for drug administration. Mice were injected daily with THC (5 mg/kg) or vehicle (Veh) in adulthood, from PND 60 to 75. Biochemical and behavioral experiments were performed from PND 90.

B Top: representative Western blots assessing mTOR activity in PFC are illustrated. Bottom: data represent the ratios of immunoreactive signals of the anti-phospho-mTOR (S2448) or anti-phospho-p70S6K (T389) antibodies to the immunoreactive signal of the anti- β -actin antibody and are expressed in % of values in vehicle-injected mice. They are the means \pm SEM of results obtained in five mice per group. $P > 0.05$, one-way ANOVA followed by Newman-Keuls test. n.s.: not significant.

C The plots represent the discrimination index for the novel object recognition task measured in each condition (new groups of THC or vehicle-injected mice during adolescence were performed). The discrimination index for the novel object recognition task is 0.24 ± 0.05 ($N = 9$) and -0.01 ± 0.05 ($N = 10$), for mice treated with vehicle and THC during adolescence, respectively, and 0.23 ± 0.05 ($N = 6$) and 0.20 ± 0.03 ($N = 12$), for mice treated with vehicle and THC in adulthood, respectively. $***P < 0.001$ and n.s. $P > 0.05$, one-way ANOVA followed by Bonferroni test. Error bars correspond to the mean \pm SEM and the dotted line to a discrimination index equal to zero.




Figure EV4. Administration of CPPQ during adolescence prevents the alterations of layer V pyramidal neuron intrinsic properties.

A–D Mice injected daily with either vehicle (Veh) or THC from PND30 to 45 were concomitantly treated with CPPQ (2.5 mg/kg, Veh/CPPQ: $n = 8$ from $N = 4$ and THC/CPPQ: $n = 10$ from $N = 4$). Electrophysiological recordings were performed from PND 60. The plots represent means \pm SEM of RMPs, AP thresholds, rheobases, and firing rates (measured as described in the legend to Fig 5), respectively. n.s.: $P > 0.05$, unpaired Student's t test. RMP: -68.4 ± 2.0 and -68.3 ± 1.2 mV for Veh/CPPQ and THC/CPPQ, respectively; AP threshold: -33.9 ± 2.0 and -34.2 ± 0.9 mV for Veh/CPPQ and THC/CPPQ conditions, respectively; Rheobase: 644 ± 66 and 574 ± 48 pA for Veh/CPPQ and THC/CPPQ conditions, respectively.